[go: up one dir, main page]

WO2010032958A3 - 아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법 - Google Patents

아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법 Download PDF

Info

Publication number
WO2010032958A3
WO2010032958A3 PCT/KR2009/005271 KR2009005271W WO2010032958A3 WO 2010032958 A3 WO2010032958 A3 WO 2010032958A3 KR 2009005271 W KR2009005271 W KR 2009005271W WO 2010032958 A3 WO2010032958 A3 WO 2010032958A3
Authority
WO
WIPO (PCT)
Prior art keywords
solid dispersion
preparation
adefovir dipivoxil
stabilized solid
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/005271
Other languages
English (en)
French (fr)
Other versions
WO2010032958A2 (ko
Inventor
이용택
윤명식
홍혜숙
조일환
안태군
이시범
장해종
박미경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ CheilJedang Corp filed Critical CJ CheilJedang Corp
Priority to US13/119,154 priority Critical patent/US20110201575A1/en
Priority to CN2009801357776A priority patent/CN102149715A/zh
Priority to EP09814774A priority patent/EP2332941A4/en
Priority to JP2011526818A priority patent/JP2012502902A/ja
Publication of WO2010032958A2 publication Critical patent/WO2010032958A2/ko
Publication of WO2010032958A3 publication Critical patent/WO2010032958A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 뉴클레오티드 유사체인 9-[2-[[비스[(피발로일옥시)메틸]포스포노]메톡시]에틸]아데닌을 포함하는 안정성이 개선된 무정형 고체 분산체, 이를 포함하는 약제학적 조성물 및 당해 고체 분산체의 제조방법에 관한 것이다.
PCT/KR2009/005271 2008-09-17 2009-09-16 아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법 Ceased WO2010032958A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/119,154 US20110201575A1 (en) 2008-09-17 2009-09-16 Stabilized solid dispersion of adefovir dipivoxil and preparation method thereof
CN2009801357776A CN102149715A (zh) 2008-09-17 2009-09-16 肝适能的稳定化固态分散物及其制备方法
EP09814774A EP2332941A4 (en) 2008-09-17 2009-09-16 STABILIZED SOLIDS DISPERSION FROM ADEFOVIR-DIPIVOXIL AND PROCESS FOR THE PRODUCTION THEREOF
JP2011526818A JP2012502902A (ja) 2008-09-17 2009-09-16 アデホビルジピボキシルの安定化した固体分散体及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080090869 2008-09-17
KR10-2008-0090869 2008-09-17

Publications (2)

Publication Number Publication Date
WO2010032958A2 WO2010032958A2 (ko) 2010-03-25
WO2010032958A3 true WO2010032958A3 (ko) 2010-06-24

Family

ID=42040002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005271 Ceased WO2010032958A2 (ko) 2008-09-17 2009-09-16 아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법

Country Status (7)

Country Link
US (1) US20110201575A1 (ko)
EP (1) EP2332941A4 (ko)
JP (1) JP2012502902A (ko)
KR (1) KR100983322B1 (ko)
CN (2) CN104173356A (ko)
TW (1) TWI389915B (ko)
WO (1) WO2010032958A2 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100031045A (ko) * 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
CN103338754A (zh) * 2010-12-10 2013-10-02 西格玛制药实验有限责任公司 口服活性核苷酸类似物或口服活性核苷酸类似物前药的高度稳定组合物
WO2013029198A1 (zh) * 2011-08-29 2013-03-07 天津泰普药品科技发展有限公司 阿德福韦酯固体制剂及其制备方法
EP3116481A1 (en) * 2014-03-13 2017-01-18 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
USD773539S1 (en) 2015-04-02 2016-12-06 Samsung Electronics Co., Ltd. Refrigerator
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
USD797820S1 (en) 2015-09-16 2017-09-19 Samsung Electronics Co., Ltd. Refrigerator
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451340B1 (en) * 1997-07-25 2002-09-17 Gilead Sciences, Inc. Nucleotide analog compositions
CN1374314A (zh) * 2002-03-13 2002-10-16 上海仲夏化学有限公司 阿德福韦酯无定形固化物及制备方法
CN1698623A (zh) * 2005-03-30 2005-11-23 美德（江西）生物科技有限公司 无结晶型态的抗乙肝病毒药物分散组合物及其药物制剂
KR100624214B1 (ko) * 1998-12-15 2006-09-18 길리애드 사이언시즈, 인코포레이티드 약제학적 제제
CN1903208A (zh) * 2005-07-28 2007-01-31 重庆圣华曦药业有限公司 阿德福韦酯口崩片药物制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
ID28006A (id) * 1997-07-25 2001-05-03 Gilead Sciences Inc Komposisi analog nukleotida
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6635278B1 (en) * 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
WO2002070013A1 (en) * 2001-03-06 2002-09-12 Kyowa Hakko Kogyo Co., Ltd. Utilization of spray-dried powder containing sugar alcohol
KR100504021B1 (ko) * 2001-12-29 2005-07-27 제일약품주식회사 난용성 약물의 고체분산체 및 이를 함유하는 경구용 항진균제 조성물
CN1515262A (zh) * 2003-01-01 2004-07-28 浙江海力生制药有限公司 阿德福韦酯肠溶制剂
CN100384426C (zh) * 2003-12-05 2008-04-30 天津药物研究院 一种含活性成分阿德福韦或其盐的固体分散物及其制备方法
CN1686146A (zh) * 2005-03-28 2005-10-26 李志海 阿德福韦酯和聚乙烯吡咯烷酮玻璃态固溶体及其制备方法
CN1879635A (zh) * 2005-06-13 2006-12-20 博瑞生物医药技术(苏州)有限公司 阿德福韦酯的β－环糊精包合物及其制剂
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
CN100417658C (zh) * 2006-05-11 2008-09-10 江苏吴中苏药医药开发有限责任公司 无定形阿德福韦酯的制备方法及其药物组合物
CN101622302B (zh) * 2007-01-26 2013-01-23 Isp投资公司 生产喷雾干燥产品的制剂工艺方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451340B1 (en) * 1997-07-25 2002-09-17 Gilead Sciences, Inc. Nucleotide analog compositions
KR100624214B1 (ko) * 1998-12-15 2006-09-18 길리애드 사이언시즈, 인코포레이티드 약제학적 제제
CN1374314A (zh) * 2002-03-13 2002-10-16 上海仲夏化学有限公司 阿德福韦酯无定形固化物及制备方法
CN1698623A (zh) * 2005-03-30 2005-11-23 美德（江西）生物科技有限公司 无结晶型态的抗乙肝病毒药物分散组合物及其药物制剂
CN1903208A (zh) * 2005-07-28 2007-01-31 重庆圣华曦药业有限公司 阿德福韦酯口崩片药物制剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2332941A4 *

Also Published As

Publication number Publication date
TWI389915B (zh) 2013-03-21
EP2332941A2 (en) 2011-06-15
TW201014866A (en) 2010-04-16
JP2012502902A (ja) 2012-02-02
US20110201575A1 (en) 2011-08-18
KR20100032342A (ko) 2010-03-25
CN104173356A (zh) 2014-12-03
CN102149715A (zh) 2011-08-10
WO2010032958A2 (ko) 2010-03-25
EP2332941A4 (en) 2012-08-08
KR100983322B1 (ko) 2010-09-20

Similar Documents

Publication Publication Date Title
WO2010032958A3 (ko) 아데포비어 디피복실의 안정화된 고체 분산체 및 이의 제조 방법
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
WO2004096286A3 (en) Antiviral phosphonate analogs
MA32341B1 (fr) Dérivés de 3h- [1, 2, 3] triazolo [4, 5, d] pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi3, et leurs synthèses
WO2008067119A3 (en) Novel compounds
WO2009048993A3 (en) Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008051805A3 (en) Triazolo-pyridazine protein kinase modulators
WO2007056596A3 (en) Phosphoramidate derivatives of fau
ZA201107412B (en) Methods for the preparation of [2-8,9-dioxo2,6-diazabicyclo[5.2.0]non-1(1)-en-2-yl)ethyl]phosphonic acid and precursors thereof
MX2009005368A (es) Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
WO2007113857A3 (en) Modified release clopidogrel formulation
PL2021002T3 (pl) Kompozycja farmaceutyczna zawierająca medoksomil olmesartanu
WO2009061909A3 (en) Wet granulation using a water sequestering agent
ZA200809171B (en) Process for the preparation of pyrazolylaminoquinazoline derivatives comprising a phosphate group
UA91655C2 (ru) Моносоль малеиновой кислоты противовирусного препарата и содержащая ее фармацевтическая композиция
WO2008024389A3 (en) Amphiphilic nucleotide cochleate compositions and methods of using the same
AU2007270897A8 (en) Novel process for the preparation of bisphosphonic acids
WO2007138462A3 (en) Aqueous oral formulations of risperidone
WO2008054767A3 (en) N4 modifications of pyrimidine analogs and uses thereof
WO2008054795A3 (en) Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
EP2230239A4 (en) PROCESS FOR PREPARING 4- [9- (6-AMINOPURINE)] - 2- (S) -HYDROXYL-BUTTERIC ACID METHYL ETERER
WO2010056847A3 (en) Lyophilization formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980135777.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09814774

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2009814774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009814774

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011526818

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13119154

Country of ref document: US